Express Healthcare
Home  »  News  »  Teknova completes US FDA notification for room temperature-stable VTM

Teknova completes US FDA notification for room temperature-stable VTM

0 46
Read Article

Eliminating the need for refrigeration of samples will boost coronavirus testing worldwide

Teknova has completed the process of US FDA notification for its Active Viral Transport Medium (ATM). ATM is a room temperature-stable version of Teknova’s CDC formulation Viral Transport Medium (VTM) and is manufactured under GMP conditions in compliance with ISO 13485 standards.

The requirement for refrigerated storage and transport of nasopharyngeal samples for viral testing poses significant logistical and financial challenges that have increased dramatically with mass COVID-19 testing. Teknova’s proven track record of rapid product development and expertise in media formulation make the company ideally placed to face these challenges head-on.

As as a company release, after sample collection, ATM maintains viral stability at room temperature for up to 72 hours and can also be stored at room temperature prior to use. ATM is tested for pH (USP <791>), conductivity (USP <644>) and sterility, and additional quality control is applied in the form of bioburden testing (USP <61>). Using bovine serum albumin for ATM instead of foetal bovine serum (FBS) provides better lot-to-lot consistency and eliminates the risk of RNA degradation by RNases present in FBS, giving users and clinicians greater confidence in their test results.

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More